design: Sentis Cancer + Discovery panel  selects 816 genes related to the development, diagnosis, treatment and prognosis of solid tumors, and uses the target region capture technology of independent intellectual property rights of BGI and high-throughput sequencing platform DNBSEQ-G400/DNBSEQ T7 for testing, the testing report is based on the BGI Shizhen Database, which provides comprehensive medication guidance on targeted therapy, chemotherapy, and immunotherapy for patients with solid tumors, as well as hereditary tumor risk assessment, to comprehensively assist patients in finding treatment options that may be of benefit.